The U.S. Centers for Disease Control's vaccine advisory committee voted to recommend the single-dose vaccine, Vimkunya, for the prevention chikungunya in 12 years and older traveling to a country ...

Bavarian Nordic's own pipeline is led by its universal COVID-19 booster candidate, which is due to start phase 3 later this year, and respiratory syncytial virus (RSV) candidate that should ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

March 31 (Reuters) - Denmark's Bavarian Nordic (BAVA.CO), opens new tab said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.

Bavarian Nordic is a developer and provider of vaccines for public health and travel immunizations. This way, BVNKF helps prevent the spread of infectious diseases across borders. They’re ...

The updated recommendations are pending final approval by the director of the CDC and the Department of Health and Human Services.

Recommendation of first chikungunya vaccine for persons as young as 12 years old expands access for US travelers to regions with outbreak or ...

A recent study carried out at Charité Universitätsmedizin Berlin and published in The Lancet Infectious Diseases has shown that one dose of Bavarian Nordic’s Jynneos (smallpox and mpox vaccine ...

For meningococcal vaccines, ACIP recommended that GSK's pentavalent vaccine (Penmenvy), designed to protect against A, B, C, ...

The US Food and Drug Administration (FDA) has approved the freeze-dried formulation of Bavarian Nordic’s smallpox and mpox vaccine in a move expected to provide flexibility in stockpiling the jab.

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ...